オクヤマ　リョウ   OKUYAMA Ryo   奥山 亮    所属   立命館アジア太平洋大学  国際経営学部    職種   教授
言語種別	英語
発行・発表の年月	2024/10
形態種別	学術論文
査読	査読あり
標題	Developer and Partnership Differences in COVID-19 and Other Infections: Insights from DNA Vaccines.
執筆形態	単著
掲載誌名	Journal of Market Access & Health Policy
掲載区分	国外
巻・号・頁	12(4),pp.317-325
担当区分	筆頭著者,最終著者,責任著者
著者・共著者	Ryo Okuyama
概要	Historically, vaccine development has relied on public support, while private biopharma has driven innovation in new therapies. During COVID-19, emerging biopharma, in partnership with large corporations and public institutions, rapidly developed vaccines using mRNA and adenoviral vector technologies, highlighting the importance of emerging bipharma and public–private partnerships in advancing new vaccine methods. This study analyzed DNA vaccine development and found that while COVID-19 development relied on emerging biopharma and private–public collaborations, vaccine development for other diseases was primarily led by public organizations. Future vaccine strategies should consider each disease’s unique characteristics.